BC Extra | Nov 29, 2018
Preclinical News

Chemputer automates drug synthesis

A University of Glasgow team developed an app-controlled robotic platform that enables the automated chemical synthesis and purification of drugs by including software that converts written chemistry protocols into code that drives production. Manual chemical...
BC Week In Review | May 11, 2015
Company News

Eisai, Glenmark neurology news

Eisai and Glenmark settled patent litigation relating to Eisai’s Banzel rufinamide for seizures. Under the settlement terms, Glenmark will be permitted to market a generic version of Banzel in the U.S. on May 30, 2022,...
BC Week In Review | Mar 16, 2015
Clinical News

Banzel rufinamide regulatory update

FDA approved an sNDA from Eisai for Banzel rufinamide as an adjunct treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ages 1-4. Eisai markets the triazole derivative in the U.S. as Banzel and...
BC Week In Review | Oct 20, 2014
Clinical News

Banzel rufinamide regulatory update

FDA accepted and granted Priority Review to an sNDA from Eisai for Banzel rufinamide as an adjunct treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ages 1-3 years. The PDUFA date is Feb....
BC Extra | Oct 15, 2014
Company News

Priority Reviews for Eisai's lenvatinib and rufinamide

Eisai Co. Ltd. (Tokyo:4523) said FDA accepted for filing and granted Priority Review to an NDA for lenvatinib ( E7080 ) and an sNDA for rufinamide ( E2080 ). Eisai is seeking approval of lenvatinib to treat progressive,...
BC Week In Review | Jan 6, 2014
Company News

Eisai sales and marketing update

On Jan. 2, Eisai said it would launch Fycompa perampanel in the U.S. on Jan. 6 as adjunct treatment for partial onset seizures in patients with epilepsy ages 12 years and older. The wholesale acquisition...
BC Week In Review | Apr 8, 2013
Company News

Eisai sales and marketing update

Eisai launched NerBloc botulinum toxin type B intramuscular injection 2,500 unit in Japan to treat cervical dystonia. Each vial has a National Health Insurance (NHI) list price of ¥28,902 ($307). In 2000, Eisai received Japanese...
BC Week In Review | Jan 7, 2013
Company News

Eisai sales and marketing update

Eisai launched Inovelon rufinamide oral suspension in Spain for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients four years of age and older. Eisai markets the triazole derivative in the U.S....
BC Week In Review | Sep 3, 2012
Clinical News

Inovelon rufinamide regulatory update

Eisai submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) for rufinamide as an adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome (LGS). Eisai markets the triazole derivative for patients >4...
BC Extra | Aug 31, 2012
Company News

Eisai seeks approval of rufinamide in Japan

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) for rufinamide as an adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome (LGS). Eisai markets the triazole...
Items per page:
1 - 10 of 47